Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial)

Karow, Anne; Reimer, Jens; König, Hans Helmut; Heider, Dirk; Bock, Thomas; Huber, Christian; Schöttle, Daniel; Meister, Klara; Rietschel, Liz; Ohm, Gunda; Schulz, Holger; Naber, Dieter; Schimmelmann, Benno G; Lambert, Martin (2012). Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial). Journal of clinical psychiatry, 73(3), e402-8. Memphis, Tenn.: Physicians Postgraduate Press

Full text not available from this repository.

To compare the 1-year cost-effectiveness of therapeutic assertive community treatment (ACT) with standard care in schizophrenia. ACT was specifically developed for patients with schizophrenia, delivered by psychosis experts highly trained in respective psychotherapies, and embedded into an integrated care system.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > University Psychiatric Services > University Hospital of Child and Adolescent Psychiatry and Psychotherapy
UniBE Contributor:	Schimmelmann, Benno Karl Edgar
ISSN:	0160-6689
Publisher:	Physicians Postgraduate Press
Language:	English
Submitter:	Myriam Pyrlik
Date Deposited:	04 Oct 2013 14:36
Last Modified:	05 Dec 2022 14:11
PubMed ID:	22490266
URI:	https://boris.unibe.ch/id/eprint/14643 (FactScience: 221716)